Macbeth. Twelfth Night. Richard III. Romeo and Juliet. No Man’s Land. Waiting For Godot. Betrayal. The Winslow Boy.

The syllabus for a university survey course in drama? No. Instead, it’s the roster of eight of the 16 titles scheduled to open on Broadway between now and the end of 2013.

To be sure, British plays, artists and productions haven’t ever been strangers to Broadway, but this preponderance of works – featuring actors such as Jude Law, Mark Rylance, Rachel Weisz, Daniel Craig, Anne-Marie Duff, Stephen Fry, Orlando Bloom, Roger Rees, Ian McKellen and Patrick Stewart – in the 40 theatres that comprise Broadway, all at the same time, is an embarrassment of riches. Add in concurrent Off-Broadway productions of A Midsummer Night’s Dream with David Harewood and Kathryn Hunter (opening the new Theatre for a New Audience space in Brooklyn) and Michael Gambon and Eileen Atkins in All That Fall, and it appears that Anglophilia is running rampant in the playhouses of New York.

Much of this is coincidence, since it’s not as if producers conspire on themes. Indeed, from a marketing standpoint, it’s not necessarily even a good idea, since the theatregoers most drawn to this work may have to face some tough buying decisions unless they have unlimited resources and time. Cultural tourists won’t even be able to fit all of these terrific sounding shows in, should they fly to the city for merely a long weekend.

But whether the productions are transfers from the UK or newly minted in America, as is the case with No Man’s Land, Romeo and Juliet, and Betrayal, the British imprimatur seems as if it’s a requirement this year, even if only in part. UK director David Leveaux is staging Romeo and Juliet with a North American cast capped by Bloom. US director Julie Taymor tapped Harewood and Hunter for A Midsummer Night’s Dream, her first project since the highly-publicised and contentious Spiderman: Turn Off The Dark (a tell-all book by her collaborator Glen Berger will be released just as Midsummer performances begin). Even the US classic The Glass Menagerie is being helmed by John Doyle. Only Classic Stage Company’s Romeo and Juliet, with Elizabeth Olsen and TR Knight, is wholly comprised of American artists, though their Romeo is Japan-born.

The English theatre can certainly take pride in this abundance of talent exported to American shores, and I look forward to each and every one of these shows enthusiastically. Indeed, I’ll pass on my annual autumn trip to London since I’ll need only take the subway and not British Airways.

But it does beg the question of whether classical work can succeed on Broadway without a UK connection. Are producers giving up on our best American actors and directors taking on British and Irish pieces without at least some of that heritage in the shows’ DNA? To be sure, not-for-profit companies may lean American overall (LCT’s Macbeth is Ethan Hawke), but has public television conditioned us to desire the “genuine” article? Great American plays appear on British stages frequently, ranging from A View From The Bridge to Fences to Clybourne Park, without the perpetual need to import Americans, let alone the cream of American talent, to make them work. Yet the power of UK casting appears to be such that even multiple Macbeths are deemed economically viable, with Alan Cumming having played virtually all of the roles on Broadway only months ago and Kenneth Branagh due at the Park Avenue Armory in June 2014.

I don’t like calling attention to national divisions when it comes to art, but the fall theatre season in New York simply can’t be overlooked. Despite the luxury of all of the great theatre on tap, the timing sends the message to US actors, theatre students, critics and audiences that when it comes to staging foreign classics, the talent exchange flows more strongly from west to east than in the other direction.

But looking on the bright side, perhaps this means we’ll soon enjoy one more benefit of the English stage, and be able to buy ice cream at the interval.

I’m often asked by journalists for observations about trends, on Broadway, Off-Broadway, or about theatre in general. One recent call queried me about the prevalence of shirtless men on Broadway this season, a topic on which I had little to say.

Although I was taught in my press agent days that two similar items are a coincidence but that for journalistic purposes, three similar items make a trend and get covered as such, I still tend to look at confluences on Broadway in any given season as accidents. Shows come together (or not) at certain times for many reasons, without co-ordination. But it’s hard not to look at the spring Broadway crop of one-actor shows and let it go unremarked.

In a span of only eight weeks, four of Broadway’s 40 theatres will be home to new one-person shows – all genuine plays, not musical revues or autobiographical monodramas – representing four of the ten new plays due this spring. They tell the stories of three influential women, all deceased – Hollywood agent Sue Mengers (I’ll Eat You Last), Texas governor Ann Richards (Ann) and Jesus’ mother (The Testament of Mary) – and those Scottish social climbers, The Macbeths. Not having seen any of them as yet, I know that the Scottish play has a single actor (Alan Cumming) playing every role; whether there are multiple characters portrayed in the other shows is to be seen.

Is this confluence the result of ‘star casting’ run amok? Not really, since of the four actors involved– Cumming, Bette Midler, Fiona Shaw and Holland Taylor (in alphabetical order) – only Midler is a multi-generational ‘big name’ in the U.S. The other three are all accomplished and honoured actors, and Cumming’s star has risen sharply since he joined the cast of TV’s The Good Wife, but none is necessarily box office catnip. Taylor last appeared on Broadway three decades ago in the infamous Moose Murders, while Shaw’s only prior appearance was as Medea during a brief run 11 years ago. Midler, we hear, won’t be singing, the feature of her previous Broadway forays in the 1970s.

So what to make of this monomania? In all likelihood, it’s simply a quirk of fate, but it has potentially lasting effects. As new plays on Broadway are typically launched into long lives in regional and later amateur theatres, is the theatrical canon being expanded with this work? One only has to see how Red and The Mountaintop have flourished around the US to see the Broadway effect on plays’ future lives, perhaps due to their tiny casts helping to balance out large plays elsewhere in a theatre’s season. Will these solo plays make the same journey – or are they taking the place of larger pieces that need a marketing boost to make that leap?

One-person shows place a significant burden on one person’s shoulders. In any venue, there’s the risk of the actor becoming ill or being injured; while subsidised theatres in the US often don’t use understudies – they’ll carry them on shows like these. But  will any audience want to see a substitute for the person truly charged with the singular task of holding a stage by themselves?

If the shows are hits, and do spawn future productions, they could further diminish cast sizes nationally. The economic temptation will be there, and perhaps playwrights who worry now about writing shows that require even six or seven actors will start to think in a smaller scale, to the detriment of the dramatic canon. We can ill-afford a scenario in which God of Carnage is a theatre’s ‘big’ show.

I look forward to each of these plays, which promise a variety of subject and style. But if solo shows become Broadway’s dramatic bread and butter, they’re likely to be met with the sound of one hand clapping.